Viloxazine for Attention-Deficit Hyperactivity Disorder: A Systematic Review and Meta-analysis of Randomized Clinical Trials.

Alok SinghMahesh Kumar BalasundaramAbhishek Singh

Published in: Journal of central nervous system disease (2022)

Viloxazine was found to be significantly superior to placebo in both efficacy outcomes. Adverse events and somnolence were significantly more than the placebo. The incidence was SAEs was more in the viloxazine group but was not statistically significant.

Keyphrases

attention deficit hyperactivity disorder
double blind
autism spectrum disorder
phase iii
working memory
risk factors
placebo controlled
clinical trial
type diabetes
randomized controlled trial
adipose tissue
metabolic syndrome
skeletal muscle
insulin resistance
weight loss